CLINICAL TRIALS PROFILE FOR NOXAFIL
✉ Email this page to a colleague
All Clinical Trials for Noxafil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00491764 ↗ | A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2007-06-01 | The purpose of this study is to evaluate the efficacy, safety, and tolerability of oral administration of four dosing regimens of posaconazole relative to placebo and terbinafine, in the treatment of toenail onychomycosis. |
| NCT00726609 ↗ | Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641) | Completed | Merck Sharp & Dohme Corp. | 2006-01-01 | The purpose of this postmarketing surveillance study is to collect an extensive body of data in a large patient population in every day life to investigate the safety and efficacy of NOXAFIL® (posaconazole) in the treatment of invasive fungal disease. | |
| NCT00750737 ↗ | Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) | Completed | Enzon Pharmaceuticals, Inc. | Phase 3 | 2008-06-01 | The objective of this study is to compare the safety and efficacy of ABLC versus oral Posaconazole in the prevention of invasive fungal infections in high risk patients with hematologic malignancies or hematopoietic stem cell transplant. Primary objective is to demonstrate the low toxicity rate and low rate of invasive fungal infections associated with ABLC or Posaconazole prophylaxis. Secondary objective will be to compare the cost effectiveness of these two prophylactic regimens. |
| NCT00750737 ↗ | Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) | Completed | M.D. Anderson Cancer Center | Phase 3 | 2008-06-01 | The objective of this study is to compare the safety and efficacy of ABLC versus oral Posaconazole in the prevention of invasive fungal infections in high risk patients with hematologic malignancies or hematopoietic stem cell transplant. Primary objective is to demonstrate the low toxicity rate and low rate of invasive fungal infections associated with ABLC or Posaconazole prophylaxis. Secondary objective will be to compare the cost effectiveness of these two prophylactic regimens. |
| NCT00799071 ↗ | Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD) | Completed | Radboud University | Phase 2 | 2009-02-01 | The purpose of this study is to find a dose for a twice daily regimen for posaconazole (PSZ) as prophylactic treatment in children with CGD, based on the PSZ trough level. |
| NCT00811642 ↗ | Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2008-11-01 | The purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with Posaconazole Oral Suspension in participants with IFI |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Noxafil
Condition Name
Clinical Trial Locations for Noxafil
Trials by Country
Clinical Trial Progress for Noxafil
Clinical Trial Phase
Clinical Trial Sponsors for Noxafil
Sponsor Name
